Background: Troglitazone is a new oral antidiabetic drug that increases the sensitivity of peripheral tissues to insulin. It may therefore increase the efficacy of exogenous insulin in patients with insulin-resistant diabetes mellitus.
Methods: We studied the effect of troglitazone or placebo in 350 patients with poorly controlled non-insulin-dependent (type 2) diabetes mellitus (glycosylated hemoglobin values, 8 to 12 percent; normal, 4.3 to 6.1 percent) despite therapy with at least 30 U of insulin daily. The patients were randomly assigned to receive 200 mg of troglitazone (116 patients), 600 mg of troglitazone (116 patients), or placebo (118 patients) daily for 26 weeks. Insulin doses were not increased and were reduced only to prevent hypoglycemia. Glycosylated hemoglobin, serum glucose while fasting, serum total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides were measured 5 times during an 8-week base-line period and 10 times during the 26-week treatment period. Daily insulin doses were recorded during both periods.
Results: Ninety percent of the patients completed the study. The adjusted mean glycosylated hemoglobin values decreased by 0.8 and 1.4 percentage points, respectively, in the group given 200 mg of troglitazone and the group given 600 mg of troglitazone, and fasting serum glucose concentrations decreased by 35 and 49 mg per deciliter (1.9 and 2.7 mmol per liter), respectively, despite decreases in the insulin dose of 11 percent and 29 percent (P<0.001 for all comparisons with the placebo group). Serum total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol concentrations increased slightly and serum triglyceride concentrations decreased slightly in the troglitazone-treated patients.
Conclusions: When given in conjunction with insulin, troglitazone improves glycemic control in patients with type 2 diabetes mellitus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJM199803263381302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Associations of glycemic status with dynamic disease trajectories of atrial fibrillation and dementia.
J Prev Alzheimers Dis
January 2025
Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Background: Atrial fibrillation (AF) has been associated with elevated dementia risk, while few studies have examined the role of the optimal glycemic status in disease trajectories of AF and dementia.
Objectives: We aim to evaluate associations between glycemic status with disease trajectories of AF and dementia, as well as major dementia subtypes, including Alzheimer's disease and vascular dementia.
Design: Population-based cohort study.
Development and Validation of a Risk Prediction Model for Cognitive Frailty in Elderly Patients With Type 2 Diabetes Mellitus.
J Clin Nurs
January 2025
Department of Nursing, Jinzhou Medical University, Jinzhou, Liaoning, China.
Aims: This study aimed to develop and validate a risk prediction model for cognitive frailty in elderly patients with Type 2 diabetes mellitus (T2DM).
Design: A cross-sectional design.
Methods: From February to November 2023, a convenience sample of 430 older adults with T2DM was enrolled at a tertiary hospital in Jinzhou.
Effects of 3-month liraglutide treatment on oxidative stress and inflammation in type 2 diabetes patients with different urinary albumin-to-creatinine ratio categories.
Medicine (Baltimore)
November 2024
Department of Endocrinology of Chongqing Red Cross Hospital (People's Hospital of Jiangbei District), Chongqing, China.
This study evaluates the effects of liraglutide on albuminuria, oxidative stress, and inflammation in type 2 diabetes (T2D) patients with different urinary albumin-to-creatinine ratio (UACR) categories. We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control. Patients were categorized into 3 groups: group I (UACR < 30 mg/g); group II (30 mg/g ≤ UACR ≤ 300 mg/g); group III (UACR > 300 mg/g).
View Article and Find Full Text PDFThe effect of green tea on patients with type 2 diabetes mellitus: A meta-analysis.
Medicine (Baltimore)
November 2024
Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China.
Background: To systematically evaluate the effect of green tea on patients with type 2 diabetes.
Methods: A computer search Cochrane, PubMed, Embase, CNKI, Wanfang, VIP, and other Chinese and English databases were conducted for randomized controlled trials of green tea in the treatment of patients with type 2 diabetes. The duration of these trials spanned from the establishment of the database to January 10, 2024.
Analysis of factors related to venous thrombosis after ankle fracture combined with type 2 diabetes mellitus applying tourniquet surgery.
Medicine (Baltimore)
November 2024
Ya'an Hospital of Traditional Chinese Medicine, Ya'an, China.
The objective was to study the risk factors of venous thrombosis after ankle fracture with type 2 diabetes mellitus surgery using a tourniquet and to assess the effect of ischemic preconditioning and metformin combination therapy in preventing thrombosis. One hundred eighty patients with ankle fractures combined with type 2 diabetes mellitus treated with lower extremity tourniquet surgery between January 2020 and December 2023 were analyzed. Based on postoperative color Doppler ultrasound of both lower extremities, the patients were divided into thrombus-positive and negative groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!